Kymera Therapeutics
Yahoo Finance • 2 months ago
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Kymera Therapeutics, Inc. KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons... Full story
Yahoo Finance • 3 months ago
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics, Inc. WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein de... Full story
Yahoo Finance • 9 months ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript February 22, 2024 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44. KYMR isn't one of the 30 most popular stoc... Full story
Yahoo Finance • 10 months ago
Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc
Jared Gollob, Chief Medical Officer of Kymera Therapeutics Inc (NASDAQ:KYMR), sold 46,137 shares of the company on February 9, 2024, according to a recent SEC Filing. Kymera Therapeutics Inc is a biotechnology company focused on discoverin... Full story
Yahoo Finance • 11 months ago
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera Therapeutics, Inc. WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein de... Full story
Yahoo Finance • 11 months ago
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery.... Full story
Yahoo Finance • last year
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
KT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients Trial showed encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS)... Full story
Yahoo Finance • last year
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be presented at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition on D... Full story
Yahoo Finance • last year
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023 ASH abstract to... Full story
Yahoo Finance • last year
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announce... Full story
Yahoo Finance • last year
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
WATERTOWN, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today an... Full story
Yahoo Finance • last year
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report th... Full story
Yahoo Finance • last year
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown to be highly active compared to MDM2 smal... Full story
Yahoo Finance • last year
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can potentially accelerate KT-333’s development... Full story
Yahoo Finance • last year
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, t... Full story
Yahoo Finance • last year
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models No dose limiting toxicities obse... Full story
Yahoo Finance • last year
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose limiting toxicities observed Data o... Full story
Yahoo Finance • 2 years ago
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of liquid and solid tumors Company plans to s... Full story
Yahoo Finance • 2 years ago
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients and was generally well-t... Full story
Yahoo Finance • 2 years ago
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023; Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) deg... Full story
